PIGHI, LAURA
 Distribuzione geografica
Continente #
NA - Nord America 666
EU - Europa 373
AS - Asia 114
OC - Oceania 3
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.158
Nazione #
US - Stati Uniti d'America 663
CN - Cina 88
IE - Irlanda 83
IT - Italia 75
FR - Francia 72
SE - Svezia 57
DE - Germania 38
FI - Finlandia 22
KR - Corea 12
GB - Regno Unito 9
BE - Belgio 5
VN - Vietnam 5
AU - Australia 3
IR - Iran 3
AT - Austria 2
CA - Canada 2
ES - Italia 2
HK - Hong Kong 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CZ - Repubblica Ceca 1
EG - Egitto 1
EU - Europa 1
ID - Indonesia 1
IS - Islanda 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
RU - Federazione Russa 1
SK - Slovacchia (Repubblica Slovacca) 1
UA - Ucraina 1
Totale 1.158
Città #
Chandler 244
Ashburn 82
Dublin 80
Beijing 35
Lawrence 22
Princeton 22
Seattle 22
Redmond 20
Sindelfingen 18
Helsinki 16
Wilmington 16
Verona 15
Seoul 12
Ann Arbor 7
Pescantina 6
Ancona 5
Bonndorf 5
Brussels 5
Lappeenranta 5
New York 5
Southend 5
Milan 4
Peschiera del Garda 4
Rome 4
Tappahannock 4
Tianjin 4
Washington 4
Woodbridge 4
Xi'an 4
Dongguan 3
Fairfield 3
Frankfurt am Main 3
Levallois-perret 3
Los Angeles 3
Neumünster 3
Norwalk 3
Taizhou 3
Cambridge 2
Chiuppano 2
Dong Ket 2
Fuzhou 2
Hong Kong 2
Krakow 2
Madrid 2
San Francisco 2
San Giovanni Lupatoto 2
Trevenzuolo 2
Turin 2
Vienna 2
Bologna 1
Bratislava 1
Brescia 1
Brisbane 1
Bucharest 1
Cairo 1
Canberra 1
Cassano delle Murge 1
Changsha 1
Chicago 1
Clonee 1
Dallas 1
Dhaka 1
Dubai 1
Edinburgh 1
Fremont 1
Guangzhou 1
Gunzenhausen 1
Haikou 1
Hangzhou 1
Hebei 1
Ho Chi Minh City 1
Laurel 1
London 1
Lviv 1
Manila 1
Marino 1
Melbourne 1
Miami 1
Montignoso 1
Montréal 1
Negrar 1
Newark 1
Niagara Falls 1
Novokuznetsk 1
Padova 1
Palermo 1
Pieve di Soligo 1
Piscataway 1
Reykjavik 1
San Mateo 1
Segrate 1
Shenyang 1
Shenzhen 1
Taiyuan 1
Toronto 1
Totale 773
Nome #
Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers 63
The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters 58
Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers 53
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA 52
Real-world assessment of Fluorecare SARS-CoV-2 Spike Protein Test Kit 52
Performance of Fujirebio Espline SARS-CoV-2 rapid antigen test for identifying potentially infectious individuals 52
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination 49
Clinical assessment of FREND COVID-19 Ag test in an unselected population referred for routine SARS-CoV-2 testing 48
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series 46
Clinical Assessment of the DiaSorin LIAISON SARS-CoV-2 Ag Chemiluminescence Immunoassay 46
Monitoring of the immunogenic response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers with Snibe SARS-CoV-2 S-RBD IgG chemiluminescent immunoassay 44
Variation of Forehead Temperature during Routine Working Shift in Hospital Laboratory Personnel: Implications for SARS-CoV-2 Screening 42
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals 42
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster 42
Evaluation of indoor hospital acclimatization of body temperature before COVID-19 fever screening 40
Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination 37
Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay 35
SARS-CoV-2 Omicron infection is associated with high nasopharyngeal viral load 33
Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers 32
Serum C reactive protein predicts humoral response after BNT162b2 booster administration 30
Humoral response post-BNT162b2 single booster in pre-vaccination baseline SARS-CoV-2 seronegative and seropositive subjects 27
Association between viral load and positivization time of a SARS-CoV-2 rapid antigen test in routine nasopharyngeal specimens 22
Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers 22
Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept 21
Effect of syringe underfilling on the quality of venous blood gas analysis 20
Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity 17
Correlation Between Time to Positive Result of SARS-CoV-2 Rapid Antigen Self-Test and Viral Antigen Concentration 16
Total anti-SARS-CoV-2 antibodies measured 6 months after Pfizer-BioNTech COVID-19 vaccination in healthcare workers 16
Clinical performance of Fujirebio Lumipulse G SARSCoV- 2 Ag chemiluminescent immunoassay 15
Monoclonal gammopathy in SARS-CoV-2 infection 13
Cellular immunity against SARS-CoV-2 depends on the serological status 13
Real-world assessment of the clinical performance of COVID-VIRO ALL IN rapid SARS-CoV-2 antigen test 12
Are anti-SARS-CoV-2 S/N IgG/IgM antibodies always predictive of previous SARS-CoV-2 infection? 12
Impact of the COVID-19 pandemic on the volume of laboratory testing 12
Early kinetics of cellular immunity in recipients of bivalent BNT162b2 vaccine: a proof-of-concept study 11
Variation of Total Anti-SARS-CoV-2 Antibodies After Primary BNT162b2 Vaccination and Homologous Booster 10
Monitoring humoral and cellular immunity over 6 months after mRNA-based bivalent COVID-19 vaccine administration 10
Cost-effectiveness analysis of different COVID-19 screening strategies based on rapid or laboratory-based SARS-CoV-2 antigen testing 9
Analytical evaluation of the novel Mindray high sensitivity cardiac troponin I immunoassay on CL-1200i 9
Reliability of a single-nostril nasopharyngeal swab for diagnosing SARS-CoV-2 infection 9
Clinical assessment of SNIBE Maglumi SARS-CoV-2 antigen fully-automated chemiluminescent immunoassay 9
Serum levels of prostate specific antigen (PSA) after primary vaccination with BNT162b2 7
Humoral response is enhanced after ipsilateral double intramuscular injection of BNT162b2 COVID-19 vaccine 6
Can cellular and humoral immunity predict response to BNT162b2 bivalent booster? 6
Clinical assessment of Ortho VITROS SARS-CoV-2 antigen chemiluminescence immunoassay 4
Vaccination time does not influence total anti-SARS-CoV-2 antibodies response 4
Is mixing of blood gas syringes after collection really necessary? 3
Urine dipstick for screening plasma glucose and bilirubin in low resource settings: a proof-of-concept study 1
Totale 1.232
Categoria #
all - tutte 6.529
article - articoli 6.529
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.058


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202124 0 0 0 0 0 0 0 0 2 3 2 17
2021/2022205 29 37 7 8 10 4 4 6 14 8 26 52
2022/2023621 36 51 58 116 31 126 23 54 63 9 29 25
2023/2024382 19 30 29 45 66 48 43 71 4 25 2 0
Totale 1.232